FI962599L - Enantioselektiivinen menetelmä kiraalisten triaryylijohdannaisten ja niiden valmistuksessa käytettävien kiraalisten välituotteiden valmistamiseksi - Google Patents

Enantioselektiivinen menetelmä kiraalisten triaryylijohdannaisten ja niiden valmistuksessa käytettävien kiraalisten välituotteiden valmistamiseksi Download PDF

Info

Publication number
FI962599L
FI962599L FI962599A FI962599A FI962599L FI 962599 L FI962599 L FI 962599L FI 962599 A FI962599 A FI 962599A FI 962599 A FI962599 A FI 962599A FI 962599 L FI962599 L FI 962599L
Authority
FI
Finland
Prior art keywords
preparation
chiral
intermediates used
enantioselective method
triaryl derivatives
Prior art date
Application number
FI962599A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI962599A7 (fi
FI962599A0 (fi
Inventor
Rikki Peter Alexander
Graham John Warrellow
John Clifford Head
Ewan Campbell Boyd
John Robert Porter
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Publication of FI962599A7 publication Critical patent/FI962599A7/fi
Publication of FI962599A0 publication Critical patent/FI962599A0/fi
Publication of FI962599L publication Critical patent/FI962599L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI962599A 1993-12-22 1994-12-22 Enantioselektiivinen menetelmä kiraalisten triaryylijohdannaisten ja niiden valmistuksessa käytettävien kiraalisten välituotteiden valmistamiseksi FI962599L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939326173A GB9326173D0 (en) 1993-12-22 1993-12-22 Chemical compounds and process
PCT/GB1994/002799 WO1995017386A1 (en) 1993-12-22 1994-12-22 An enantioselective process for the preparation of chiral triaryl derivatives and chiral intermediates for use therein

Publications (3)

Publication Number Publication Date
FI962599A7 FI962599A7 (fi) 1996-06-20
FI962599A0 FI962599A0 (fi) 1996-06-20
FI962599L true FI962599L (fi) 1996-06-20

Family

ID=10747020

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962599A FI962599L (fi) 1993-12-22 1994-12-22 Enantioselektiivinen menetelmä kiraalisten triaryylijohdannaisten ja niiden valmistuksessa käytettävien kiraalisten välituotteiden valmistamiseksi

Country Status (12)

Country Link
US (1) US5608070A (cs)
EP (1) EP0736010A1 (cs)
JP (1) JPH09510691A (cs)
KR (1) KR100328191B1 (cs)
AU (1) AU689837B2 (cs)
CA (1) CA2177817A1 (cs)
CZ (1) CZ294296B6 (cs)
FI (1) FI962599L (cs)
GB (2) GB9326173D0 (cs)
HU (1) HUT76284A (cs)
NZ (1) NZ277529A (cs)
WO (1) WO1995017386A1 (cs)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
WO1995017399A1 (en) * 1993-12-22 1995-06-29 Celltech Therapeutics Limited Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9603723D0 (en) * 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
US5710170A (en) * 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
CA2238875C (en) * 1995-12-15 2003-09-16 Merck Frosst Canada Inc. Tri-aryl ethane derivatives as pde iv inhibitors
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
AR006550A1 (es) * 1996-04-17 1999-09-08 Merck & Co Inc Metodo de preparacion de inhibidores de fosfodiesterasa iv
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
PT912517E (pt) * 1996-05-08 2001-03-30 Merck & Co Inc Metodo de preparacao de inibidores de fosfodiesterase iv
US5808082A (en) * 1996-05-08 1998-09-15 Merck & Co., Inc. Method of preparing phosphodiesterase IV inhibitors
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
AU4269597A (en) * 1996-09-17 1998-04-14 Merck & Co., Inc. Process for bioreduction of bisaryl ketone to bisaryl alcohol
TW508353B (en) * 1996-09-17 2002-11-01 Merck & Co Inc Method of preparing phosphodiesterase IV inhibitors
US5900368A (en) * 1996-09-17 1999-05-04 Merck & Co., Inc. Process for bioreduction of bisaryl ketone to bisaryl alcohol
EP0931066B1 (en) * 1996-09-17 2002-05-15 Merck & Co., Inc. Method of preparing phosphodiesterase iv inhibitors
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
EP0946523A1 (en) 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
WO1999043636A2 (en) 1998-02-27 1999-09-02 The United States Of America As Represented By Thesecretary Of The Department Of Health And Human Services Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
US6316434B1 (en) 1999-03-03 2001-11-13 Merck Frosst Canada & Co. Assay for emetic activity
US6200993B1 (en) * 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
US6316472B1 (en) 1999-05-13 2001-11-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
MY123585A (en) 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
US6639077B2 (en) 2000-03-23 2003-10-28 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane PDE4 inhibitors
WO2001090076A1 (en) 2000-05-25 2001-11-29 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
US6740666B2 (en) 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
CA2447765C (en) 2001-05-24 2011-01-25 Merck Frosst Canada & Co./Merck Frosst Canada & Cie 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
HRP20031081A2 (en) * 2001-05-29 2005-10-31 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2257272B1 (cs) * 1974-01-15 1978-08-25 Pharmascience Labo
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
DE2541855A1 (de) * 1975-09-18 1977-03-31 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
SU888821A3 (ru) * 1976-12-03 1981-12-07 Шеринг Аг (Инофирма) Способ получени 5-(замещенный фенил)-оксазолидинонов или их серусодержащих аналогов
DE2962383D1 (en) * 1978-06-15 1982-05-06 Ici Plc Anti-inflammatory 1-phenyl-2-aminoethanol derivatives, pharmaceutical compositions thereof for topical use, and processes for their manufacture
US5128358A (en) * 1988-01-19 1992-07-07 Pfizer Inc. Aryl substituted nitrogen heterocyclic antidepressants
WO1987006576A1 (en) * 1986-04-29 1987-11-05 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
US4792561A (en) * 1986-05-29 1988-12-20 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors
US4921862A (en) * 1986-05-29 1990-05-01 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-amp phosphodiesterase inhibitors
US5274002A (en) * 1987-04-14 1993-12-28 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
EP0393500A1 (de) * 1989-04-17 1990-10-24 Byk Gulden Lomberg Chemische Fabrik GmbH Neue Arylpyridazine, ihre Herstellung, Verwendung und sie enthaltende Arzneimittel
DE4003919A1 (de) * 1990-02-09 1991-08-14 Basf Ag Heteroarylalkene, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
AU7854291A (en) * 1990-04-27 1991-11-27 Rorer International (Holdings), Inc. Styryl compounds which inhibit egf receptor protein tyrosine kinase
FI930077A0 (fi) * 1990-07-10 1993-01-08 Smithkline Beecham Corp Oxamider
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
WO1992006085A1 (en) * 1990-09-28 1992-04-16 Smith Kline & French Laboratories Limited Phenylpyridinol derivatives as medicaments
CA2094127A1 (en) * 1990-10-16 1992-04-17 Hermann Amschler Arylpyridazinones
JPH06501708A (ja) * 1990-11-06 1994-02-24 スミスクライン・ビーチャム・コーポレイション イミダゾリジノン化合物
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
AU1574892A (en) * 1991-04-26 1992-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyridazines
US5191084A (en) * 1991-05-01 1993-03-02 American Home Products Corporation Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
EP0540165A1 (en) * 1991-10-03 1993-05-05 Zeneca Limited Alkanoic acid derivatives
CA2080554A1 (en) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Styrene derivatives
US5326898A (en) * 1992-02-11 1994-07-05 Allergan, Inc. Substituted phenylethenyl compounds having retinoid-like biological activity
AU3738393A (en) * 1992-04-02 1993-11-08 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor
ATE282025T1 (de) * 1992-07-28 2004-11-15 Aventis Pharma Ltd Inhibitoren von c-amp phosphodiesterase
WO1994012461A1 (en) * 1992-12-02 1994-06-09 Pfizer Inc. Catechol diethers as selective pdeiv inhibitors
TW263495B (cs) * 1992-12-23 1995-11-21 Celltech Ltd

Also Published As

Publication number Publication date
FI962599A7 (fi) 1996-06-20
FI962599A0 (fi) 1996-06-20
HUT76284A (en) 1997-07-28
GB2299082A (en) 1996-09-25
EP0736010A1 (en) 1996-10-09
GB2299082B (en) 1998-06-17
WO1995017386A1 (en) 1995-06-29
JPH09510691A (ja) 1997-10-28
HU9601725D0 (en) 1996-08-28
GB9326173D0 (en) 1994-02-23
KR100328191B1 (ko) 2002-07-27
CZ181996A3 (en) 1997-02-12
NZ277529A (en) 1998-03-25
CA2177817A1 (en) 1995-06-29
AU689837B2 (en) 1998-04-09
AU1278395A (en) 1995-07-10
CZ294296B6 (cs) 2004-11-10
GB9612213D0 (en) 1996-08-14
US5608070A (en) 1997-03-04

Similar Documents

Publication Publication Date Title
FI962599L (fi) Enantioselektiivinen menetelmä kiraalisten triaryylijohdannaisten ja niiden valmistuksessa käytettävien kiraalisten välituotteiden valmistamiseksi
FI960949L (fi) Uusi lipaasi, lipaasia tuottavat mikro-organismit, menetelmä lipaasin tuottamiseksi ja lipaasin käyttö
FI960751A7 (fi) Substituoidut atsaindolylideeniyhdisteet ja menetelmä niiden valmistamiseksi
FI905228A0 (fi) Menetelmä mikro-organismien kasvun ja lisääntymisen ehkäisemiseksi
FI942123L (fi) Monivaihelateksin käyttö ja menetelmä monivaihelateksin valmistamiseksi
FI970001L (fi) Substraatin vedytys ja menetelmän mukaan valmistetut tuotteet
FI971495L (fi) Vaahdonestokoostumus ja sen käyttömenetelmä
FI964102L (fi) Menetelmä fenolin ja fenolijohdannaisten valmistamiseksi
FI930326L (fi) Pinnoiteseos ja menetelmä sen valmistamiseksi
FI971349L (fi) Asfaltin irrote ja käyttömenetelmä
FI953919A7 (fi) Pyrrolydeenimetyylijohdannaiset ja menetelmä niiden valmistamiseksi
FI880453A7 (fi) Nukutusainekoostumus ja menetelmä sen käyttämiseksi.
FI964901L (fi) Menetelmä alfa-metoksi-iminokarboksyylihappometyyliamidien valmistamiseksi ja menetelmässä käytettyjä välituotteita
FI952297L (fi) Fluoridia vapauttava hammaspohjustekoostumus ja menetelmä sen käyttämiseksi
FI933676A7 (fi) Menetelmä happojen ja emästen tuottamiseksi
FI943188L (fi) Nestekidekopolyesteri-imidit ja menetelmä niiden valmistamiseksi
FI955123A0 (fi) Kolestyramiinia sisältävä koostumus ja menetelmä tämän valmistamiseksi
FI971311L (fi) Menetelmiä syklopropaanikarboksyylihapon ja sen johdosten valmistamiseksi
FI932863A7 (fi) Menetelmä uusien tienotiatsiinijohdosten valmistamiseksi ja niiden käyttö
FI942046L (fi) Polysykliset yhdisteet ja menetelmä niiden valmistamiseksi
FI981359L (fi) Uudet tiomarinolin johdannaiset ja menetelmät niiden valmistamiseksi
FI972530L (fi) Menetelmä substituoitujen 4-etyyli-piperidiinien valmistamiseksi ja niiden valmistuksessa käytettävä välituote
FI972464A7 (fi) Diaminoeetterin diklavulanaattisuola ja menetelmä sen valmistamiseksi
FI954542A7 (fi) Mikrosuodatinlevy ja menetelmä sen valmistamiseksi
FI964709A7 (fi) Kiraalisia yhdisteitä ja niiden resoluutio

Legal Events

Date Code Title Description
MA Patent expired